LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus...

Annals of Oncology 2020 / 09 Vol. 31

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., Schenker, M., Yanez, P., Tehfe, M., Poulart, V., Cullen, D., Lei
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.2296
Date:
September, 2020
File:
PDF, 93 KB
2020
Conversion to is in progress
Conversion to is failed